934475-89-5

Upstream product

• 338394-85-7 4-(phenylacetyl)-2-(trichloroacetyl)pyrrole 
• 141-52-6 sodium ethanolate 
• 2199-43-1 ethyl 1H-pyrrole-2-carboxylate 
• 103-80-0 phenylacetyl chloride 
• 35302-72-8 pyrrol-2-yl trichloromethyl ketone 

Downstream Products

• 934475-70-4 ethyl 4-(phenylacetyl)-1-(pent-4-enyl)-pyrrole-2-carboxylate 

Relevant academic research and scientific papers

D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independentl

The intramolecular photometathesis of pyrroles

UV irradiation of various electron deficient pyrrole derivatives induces a novel methathesis sequence resulting in selective cleavage of the 2,3-pyrrole bond. The overall sequence has been shown to proceed by two discrete wavelength-dependent steps involving sequential [2+2] cyclobutane formation followed by photochemically mediated retro-[2+2] to the products. Copyright

Pyrrole and pyrazole DAAO inhibitors

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5; or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR6R7)n; R3 is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR4; R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5; R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R6 and R7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R1, R2 and R4 is other than hydrogen; and at least one of X and Y is (CR6R7)n. D-serine or cycloserine may be coadministered along with the compound of formula I.